GlassScriptPhysician profile
Kerry E Wood
NPI 1033760772
$8,268.63
in general payments reported to CMS, 2019-2025
34 companies · $1,802 in 2025
The $1,802 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,270 · 2022: $1,562 · 2023: $1,534 · 2024: $2,101 · 2025: $1,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,297 · Consulting Fee: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,297.06 |
| Consulting Fee | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,092.04 | 2021-2025 | |
| Medtronic, INC. | $854.00 | 2022-2025 | Linq II, Cobalt Dr Mri Surescan, Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.34 | 2021-2025 | Jardiance |
| Pfizer INC. | $552.76 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $522.83 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $495.80 | 2021-2025 | Lifevest |
| Amgen INC. | $430.75 | 2021-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $393.54 | 2022-2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $339.11 | 2021-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $334.34 | 2021-2025 | Verquvo, Capvaxive |
| Biotronik INC. | $319.80 | 2021-2025 | Amvia Edge |
| Astrazeneca Pharmaceuticals LP | $307.50 | 2021-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $268.28 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $225.47 | 2024-2025 | Wegovy, Ozempic |
| Scpharmaceuticals INC. | $199.73 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $148.98 | 2021-2023 | Watchman Flx |
| Kiniksa Pharmaceuticals, LTD. | $143.91 | 2021-2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $117.15 | 2022 | |
| Atricure, INC. | $90.64 | 2025 | Atriclip Laa Exclusion System |
| Kiniksa Pharmaceuticals International, Plc | $82.26 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $78.92 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.28 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $61.90 | 2021-2025 | Evkeeza |
| Abiomed | $52.43 | 2024 | Impella |
| W. L. Gore & Associates, INC. | $37.35 | 2022 | |
| Cardiva Medical, INC. | $36.32 | 2024 | Cardiva Vascade 6/7f Vcs |
| Bridgebio Pharma, INC. | $32.28 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $30.19 | 2023 | Optimizer |
| Shockwave Medical, INC | $27.52 | 2022 | |
| Abbott Laboratories | $23.35 | 2025 | Aveir |
| Altathera Pharmaceuticals LLC | $22.99 | 2025 | Sotalol Hydrochloride |
| Lilly USA, LLC | $19.39 | 2024 | Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $15.28 | 2021 | |
| Zoll Respicardia, INC. | $14.20 | 2025 | Remede System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.